Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
162
-
Total 13F shares, excl. options
-
118M
-
Shares change
-
+6.46M
-
Total reported value, excl. options
-
$365M
-
Value change
-
+$19.6M
-
Put/Call ratio
-
0.48
-
Number of buys
-
79
-
Number of sells
-
-61
-
Price
-
$3.09
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2025
198 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2025.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 162 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 118M shares
of 193M outstanding shares and own 61.07% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (24.2M shares), Whitefort Capital Management, LP (13.3M shares), BlackRock, Inc. (12.9M shares), Two Seas Capital LP (10.4M shares), VANGUARD GROUP INC (9.09M shares), STATE STREET CORP (4.46M shares), GEODE CAPITAL MANAGEMENT, LLC (3.64M shares), GOLDMAN SACHS GROUP INC (3.04M shares), ADAR1 Capital Management, LLC (2.83M shares), and BlackBarn Capital Partners LP (2.6M shares).
This table shows the top 162 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.